TIL Stock Overview
Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Instil Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.75 |
| 52 Week High | US$14.00 |
| 52 Week Low | US$6.07 |
| Beta | 1.25 |
| 1 Month Change | -3.67% |
| 3 Month Change | -8.12% |
| 1 Year Change | -15.34% |
| 3 Year Change | -97.02% |
| 5 Year Change | n/a |
| Change since IPO | -97.97% |
Recent News & Updates
Shareholder Returns
| TIL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.6% | 1.5% | 1.2% |
| 1Y | -15.3% | 1.1% | 24.7% |
Return vs Industry: TIL underperformed the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: TIL underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| TIL volatility | |
|---|---|
| TIL Average Weekly Movement | 4.5% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TIL's share price has been volatile over the past 3 months.
Volatility Over Time: TIL's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 49 | Bronson Crouch | instilbio.com |
Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies.
Instil Bio, Inc. Fundamentals Summary
| TIL fundamental statistics | |
|---|---|
| Market cap | US$69.92m |
| Earnings (TTM) | -US$156.09m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs TIL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TIL income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$156.09m |
| Earnings | -US$156.09m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -24.00 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 36.1% |
How did TIL perform over the long term?
See historical performance and comparison